Anil Ananthaneni, MD

Diagnostic stewardship is essential in high-stakes hematology. Reconsidering how we utilize ADAMTS13 testing for aTTP can improve diagnostic accuracy and resource allocation. Read our article published on @AjmQonline doi.org/10.1097/JMQ.00…

@HadidiSamer @umariqbalmed @JAMA_current A very refreshing read, and I agree with the points raised throughout. The trend of poor abstract-to-manuscript follow-through should be discouraged in academia.

Check our viewpoint published @JAMA_current #MedEd Abstract Factory—Research Culture Harming Medical Education The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor. ➡️jamanetwork.com/journals/jama/… @utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG

Last day at #ASH25. Excited to share that our work was selected for an Abstract Achievement Award at this year’s ASH meeting in Orlando, FL! @ASH_hematology

@SrinishantR @AjuVaniBabu Congrats! Just a friendly reminder that the abstracts including titles are embargoed until 11/03

Radiation doses of common radiological procedures #4KMedEd 🩻 ☢️ Transatlantic flight: 0.2mSv Average background radiation: 3mSv/yr

JUST IN: @US_FDA approves imlunestrant (Inluriyo, @EliLillyandCo), an ER antagonist, for adults with ER (+), HER-2 (-), ESR1-mutated metastatic breast cancer with 1+ prior endocrine therapy. Approval based on EMBER-3 published in @NEJM with 1st author @jhaveri_komal @MSKCancerCenter investor.lilly.com/news-releases/…

🚨Have you heard about the latest @US_FDA approval? ✅ #Pembrolizumab has been approved for subcutaneous administration ✅ This may offer greater convenience for patients receiving this drug, including those with #gyncancer like #EndometrialCancer and #CervicalCancer ➡️ More info: fda.gov/drugs/resource… ❓ What are your thoughts about this new approval? @leitaomd @karenluMD @LAMcAlarnenMD @JCohenMD @pedroramirezMD @GynCancerMD @amandanfader @BillzamMD @RyanKahnMD1 @GreggNelsonERAS @ShannonWestin @gyncsm #gyncsm #oncology @OncBrothers @PGrivasMDPhD @CParkMD #gcam @KEYTRUDA

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer @FordePatrick et al. nejm.org/doi/full/10.10…

Postoperative radiotherapy and survival outcomes in pN2 non-small-cell lung cancer with positive surgical margins: An updated review of the National Cancer Database #ASCO ascopubs.org/doi/abs/10.120…

A pleasant surprise in the mail today and honored to be recognized as a top reviewer for JCO Oncology Practice! As an author, I know how much a timely/quality peer review matters. Grateful to contribute to the process! Thank you @ASCO @JCOOP_ASCO

TMA in adult onset Still’s disease is a very rare entity with poor outcomes (>50% permanent complication rate). Unknown if this occurs by chance or association. Please read our report on this topic! #AOSD #TMA #TTP #Still’s doi.org/10.1136/bcr-20…

#Weekend_review #TP53 #AML #COMMAND_Consortium 1/ I will share our collaborative effort in looking at different aspects of TP53 mutated AML: 🧵 (1) impact of induction strategy on outcome 10.1002/ajh.26546 (2) Transplant outcome 10.1038/s41375-023-01847-7 (3) Racial disparities in treatment and outcomes 10.1002/cncr.34604 (4) Impact of venetoclax addition to HMA on response and survival 10.1038/s41408-024-01000-2 (5) Impact of “single” vs “multi-hit” TP53 10.3324/haematol.2024.285000 I can not thank enough to all the collaborators of #COMMAND_consortium 🙏🙏🙏

@UGrewalMD @LSUHS @LSUHSResearch Thank you Udhay! The peer reviews and revisions took more than a year but we are really glad it’s finally out with open access, fully sponsored by @abhhoficial

@Ananth_MD Great work Anil! Glad to see these data from @LSUHS finally out in print. Dr Mansour has been advocating for this cause for several years. @LSUHSResearch

Scheduled partial exchange transfusions were a/w decreased hospital admissions and increased gestational age at delivery in pregnant women with severe sickle cell disease. No significant differences in other natal outcomes including alloimmunization —> pubmed.ncbi.nlm.nih.gov/39322530/

Our results are similar to the TAPS2 RCT feasibility/acceptability study results published recently —> doi.org/10.1182/blooda…

Grateful to the JCO Oncology Practice editorial team and Dr. Burton for the opportunity to discuss the crucial topic of oncofertility. Read our editorial: doi.org/10.1200/OP-24-… @JCOOP_ASCO #Oncofertility #CancerCare #FertilityPreservation

Practice-changing news from #GU24: KEYNOTE-564 data support adjuvant pembro as a standard of care after surgery for patients with ccRCC at higher risk for recurrence: brnw.ch/21wGrP1 #ASCODailyNews @DrChoueiri @PBarataMD

Are We Diagnosing and Managing Diabetes in Patients with Sickle Cell Disorders Accurately? doi.org/10.1182/blood-…

Immunosuppressant Drug-Associated Non-Hodgkin Lymphoma: A Real-World Pharmacovigilance Database Analysis doi.org/10.1182/blood-…